Answers are grounded in this paper and cite their sources.
Theoretical exploration highlights how neural pathways and immune regulation affect tumor dynamics and response to therapy.
There has been a multitude of research across the extensively and intricately studied fields of psychoimmunology and cancer neuroscience. Research from both ends suggest a multifaceted interplay between the nervous and immune system, and how they influence the progression of tumors and of course the response to therapy. The purpose of this theoretical research paper will explore the bidirectional communication between neurological pathways; The sympathetic nervous system, HPA axis, and neurotransmitter signaling, while also exploring the dynamic of immune regulation within the tumor micro-environment (TME). Focusing on recent evidence which suggests that neural inputs have the potential to shape immune cell phenotypes and cytokine activity, while fully acknowledging the overall impact of external factors such as chronic stress, and circadian disruption on tumor dynamics led to the proposal of a consolidated model which neutral stress responses modulate tumor progression and immune surveillance. The overall framework focuses highly on therapeutic implications, specifically targeting neutral-immune communication to augment immunotherapies, incorporating behavioral interventions to control tumor growth induced by severe stress, and the utilization of neuromodulators to control tumor immunity. The overall conclusion will outline future interests by focusing on the need for transitional studies, the ethicality of neuroimmune targeting and said ethical considerations which could come into fruition, and the assurance of neuroimmunological integration in personalized cancer care. Citation Format: Jordan A. Stewar. The Neurological and Immunological Interplay in Cancer Progression and Treatment Response [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers—Knowledge Gaps and Research Opportunities; 2025 Dec 10-13; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(23_Suppl):Abstract nr C036.
No takes yet. Share an insight, caveat, or question.
James Steward (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: